METHODS FOR CORRECTING MITOTIC SPINDLE DEFECTS ASSOCIATED WITH SOMATIC CELL NUCLEAR TRANSFER IN ANIMALS

• US 20080263692A1
• Filed: 06/18/2008
• Published: 10/23/2008
• Est. Priority Date: 04/09/2003
• Status: Abandoned Application

• Current Assignee: Calvin R. Simerly, Christopher S. Navara, Gerald P. Schatten
• Original Assignee: Calvin R. Simerly, Christopher S. Navara, Gerald P. Schatten
• Inventors: Simerly, Calvin R., Schatten, Gerald P., Navara, Christopher S.
• Application Number:
  US12/141,572
• Publication Number:
  US 20080263692A1
• Time in Patent Office: Days
• US Class Current: 800/24
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2227/106 Primate
• CPC Class Codes: A01K 2267/03 Animal model, e.g. for test or diseases
• CPC Class Codes: A01K 67/00 Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
• CPC Class Codes: A01K 67/027 New or modified breeds of vertebrates
• CPC Class Codes: C12N 15/873 Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
• CPC Class Codes: C12N 15/8776 Primate embryos
• CPC Class Codes: C12N 5/10 Cells modified by introduction of foreign genetic material

Abstract

The present invention is directed to various methodologies to make NT a practical procedure for animals, specifically, primates including human and nonhuman primates. Furthermore, the methods and molecular components provided by the present invention provide a practical means for producing embryos with desired characteristics. In a specific embodiment, we methodology of the present invention comprises introducing nuclei having desired characteristics along with one or more molecular components into an egg, culturing the egg to produce a viable embryo, transferring the embryo to the oviducts of a female, and producing a cloned animal.

Claims

1-84. -84. (canceled)

85. A method comprising the steps of:

introducing a nucleus along with one or more molecular components selected from the group consisting of a centrosome protein, a centrosomal component from a sperm centrosome, a mitotic motor protein, and combinations thereof, into an enucleated egg;

activating said egg; and

culturing said egg to produce a primate embryo.

86. The method of claim 85, wherein said nucleus has desired characteristics.

87. The method of claim 86, wherein said desired characteristics are linked to a specific disease or disorder.

88. The method of claim 87, wherein said specific disease or disorder is selected from the group consisting of cardiovascular disease, neurological disease, reproductive disorder, cancer, eye disease, endocrine disorder, pulmonary disease, metabolic disorder, autoimmune disorder, and aging.

89. The method of claim 85, wherein said introducing step comprises performing SCNT.

90. The method of claim 89, further comprising the step of performing pronuclear removal after SCNT.

91. The method of claim 89, further comprising the step of performing a second nuclear transfer following said SCNT.

92. The method of claim 85, wherein said introducing step further comprises performing meiotic spindle collapse.

93. The method of claim 85, further comprising the step of performing ooplasmic supplementation following said introducing step.

94. The method of claim 93, wherein said ooplasmic supplementation is perform by ooplast electrofusion.

95. The method of claim 93, wherein said ooplasmic supplementation is performed by microinjection.

96. The method of claim 85, wherein said one or more molecular components comprise centrosomal components normally present in sperm centrosomes.

97. The method of claim 85, wherein said one or more molecular components comprise mitotic motor proteins and centrosome proteins.

98. The method of claim 97, wherein said mitotic motor proteins comprise kinesins.

99. The method of claim 98, wherein said kinesins comprise HSET kinesin.

100. The method of claim 97, wherein said centrosome proteins comprise NuMA.

101. The method of claim 85, wherein said embryo is transgenic.

102. The method according to claim 85 wherein said nucleus is obtained from a donor cell selected from the group consisting of a dissociated granulose cell, an endothelial cell, an isolated ICM cell derived from a blastocyst and a primary fibroblast cell line.